SOMERVILLE, MA--(Marketwire - October 27, 2008) - Thermedical, a privately held company currently developing a proprietary ablation therapy for the treatment of cancer, announced today that it has received a $3.6 million Competing Phase 2 Renewal Grant from the National Heart, Lung and Blood Institute. The three-year grant will fund continued development and testing of the company's Saline Enhanced Radiofrequency Ablation (SERF) system, which is designed for use in ablation treatment for ventricular tachycardia (VT).
